組織金屬蛋白酶抑制因子3(TIMP3)多克隆抗體
Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
SFD; TIMP Metallopeptidase Inhibitor 3; Metallopeptidase Inhibitor 3; Sorsby Fundus Dystrophy; Pseudoinflammatory
- 編號PAA129Fi01
- 物種Danio rerio (Zebrafish,斑馬魚)相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原-
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有0.02% NaN3和50%甘油)
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù),請參見流式抗體。 - 下載英文說明書 中文說明書
- 規(guī)格20μl100μl200μl1ml10ml
- 價格¥ 810 ¥ 1890¥ 2700¥ 6750¥ 27000
- 欲了解實(shí)際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對TIMP3的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗中能識別TIMP3。
用法
免疫印跡:0.2-2μg/mL;1:250-2500
免疫組織化學(xué):5-20μg/mL;1:25-100
免疫細(xì)胞化學(xué):5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Danio rerio (Zebrafish,斑馬魚) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA129Fi01 | 組織金屬蛋白酶抑制因子3(TIMP3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA129Fi01 | 組織金屬蛋白酶抑制因子3(TIMP3)多克隆抗體 | WB; IHC; ICC; IP. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Neuroimmunomodulation | Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis Virus[Pubmed: source] |
Experimental Biology and Medicine | Acidic pH conditions mimicking degenerative intervertebral discs impair the survival and biological behavior of human adipose-derived mesenchymal stem cells[Rsmjournals: Source] |
PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches[Plosone: Source] |
Physiol. Res. | The unwounded skin remodeling in animal models of diabetes types 1 and 2.[Pubmed: 24020818] |
VirusDisease | Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection[Pubmed:26925446] |
Acta Pharmacol Sin. | Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.[pubmed:27890915] |
Biochemical genetics | Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancer[pubmed:28421310] |
International Journal of Cancer | Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma[Pubmed: 30650187] |
J. Pers. Med | Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease[Pubmed:35629249] |